Interferon-beta inhibits liver metastases from murine colon 26 carcinoma and its highly metastatic variant

Surg Today. 2007;37(6):474-81. doi: 10.1007/s00595-006-3418-z. Epub 2007 May 28.

Abstract

Purpose: The antitumor effects of Interferon-beta (IFN-beta) are due to its direct inhibition of cell proliferation, immunostimulatory activity, and the inhibition of angiogenesis. We investigated the mechanism of the effects of IFN-beta on a murine colon 26 cell line (CT 26) and its highly metastatic variant (L5).

Methods: We examined its inhibitory effects on cell proliferation in vitro and the development of liver metastases in vivo.

Results: The proliferation of CT 26 in vitro was inhibited by IFN-beta in a dose- and time-dependent manner. The number of metastases was reduced in mice inoculated with CT 26 (P<0.01) and L5 (P<0.01) on Day 14 after treatment with IFN-beta. The median survival rate of the mice inoculated with L5 administered IFN-beta every other day, or every day was higher than in the control group (P<0.05). A dorsal air sac assay demonstrated that IFN-beta inhibited angiogenesis in mice inoculated with CT 26, but the effects disappeared with aminoguanidine, an inducible nitric oxide synthase inhibitor.

Conclusion: These results showed that IFN-beta directly inhibits the proliferation of CT 26. In addition, the in vivo experiments suggested that IFN-beta might effectively inhibit liver metastases.

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • Disease Models, Animal
  • Female
  • Interferon Type I / pharmacology
  • Interferon Type I / therapeutic use*
  • Liver Neoplasms, Experimental / drug therapy*
  • Mice
  • Mice, Inbred BALB C
  • Recombinant Proteins

Substances

  • Antineoplastic Agents
  • Interferon Type I
  • Recombinant Proteins